SYDNEY, Nov. 19 (Xinhua) -- Experimental nose drops using mRNA technology have enhanced learning and memory in aged mice and prevented memory loss in a mouse model of Alzheimer's disease, Australian research has found.
The research will lead to a new way to treat diseases of the brain, allowing for the development of medicines that target major neurological diseases, including neurodegeneration, stroke, traumatic brain injury and rare genetic and developmental diseases, according to a statement released Thursday by Australia's University of Sydney.
"If we can proceed quickly to clinical trials in humans, this approach could represent a world-first non-invasive delivery system to treat Alzheimer's that bypasses the blood-brain barrier," said Professor Greg Neely at the university's Charles Perkins Center.
The findings, published in Advanced Science, show that delivering messenger RNA (mRNA) packaged in lipid nanoparticles can turn the nose into a drug factory, producing medically active proteins that can enter the brain and increase cognitive ability.
The study focused on delivering mRNA instructions to build brain-derived neurotrophic factor (BDNF), a naturally occurring protein that supports neuron survival, plasticity and memory formation. Reduced BDNF levels are associated with ageing and Alzheimer's disease.
In tests, aged mice that had shown a decline in cognitive ability but received the nose drops performed similarly to young mice in assessments of working memory, spatial memory and object recognition.
Researchers found that treatment twice a week protected mice in a genetic model of Alzheimer's disease against the cognitive decline normally seen as the disease progressed.
The treatment appeared to preserve brain function without reducing amyloid plaques, protein clumps associated with Alzheimer's disease, suggesting it could potentially complement existing therapies, according to the researchers. ■
